Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1)
AssigneeBiocan Limited
InventorsJoy Mathew, Chandrashekar Aswathanarayanappa, Tom Thomas Puthiaparampil
Life of this patent
Estimating the term…
Abstract
Crystalline and amorphous polymorphic forms of Atorvastatin magnesium and processes for their preparation are claimed.
Claims24
1-18. (canceled)
Crystalline form of Atorvastatin magnesium.
Amorphous form of Atorvastatin magnesium.
Crystalline form B1 of Atorvastatin magnesium.
Crystalline form B2 of Atorvastatin magnesium.
Amorphous form B3 of Atorvastatin magnesium.
A process for preparation of crystalline form of Atorvastatin magnesium comprising:
- a. treating Atorvastatin magnesium with one or more solvents or solvent mixtures,
- b. optionally subjecting the mixture to a suitable temperature range, stirring, filtering the mixture, and
- c. isolating the crystalline form of Atorvastatin magnesium.
A process for the preparation of amorphous form of Atorvastatin magnesium comprising:
- a. treating Atorvastatin magnesium with one or more solvents or solvent mixtures, and
- b. isolating the amorphous form of Atorvastatin magnesium.
A pharmaceutical composition comprising atorvastatin magnesium form B1, B2 or B3.
A method of treatment or prevention of cholesterolemia in a subject comprising administering to the subject atorvastatin magnesium form B1, B2 or B3.
Dependencies are inferred from the claim text.